Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Why Smoking Increases The Risk Of Heart Disease And Strokes
Researchers at Charles Drew University of Medicine and Science in Los Angeles and Western University of Health Sciences in Pomona have discovered a reason why smoking increases the risk of heart disease and strokes.
generic viagra online
Raptor Pharmaceuticals Doses First Patient In Phase 2b Clinical Trial Of DR Cysteamine For Cystinosis
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced that it has dosed the first patient in its Phase 2b clinical trial, conducted in collaboration with the University of California, San Diego ("UCSD"), to evaluate Raptor"s proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare genetic lysosomal storage disease. Under Raptor"s open Investigational New Drug application ("IND"), UCSD is performing the Raptor-sponsored trial at its General Clinical Research Center.
News of the day
Jaloma Pacifiers Recalled Due To Choking Hazard
The Connecticut Department of Consumer Protection is notifying consumers about a voluntary recall announced by the U.S. Consumer Product Safety Commission. The recalled Jaloma Pacifiers were sold in retail stores in New Jersey and New York from February 2008 through March 2009, for approximately $1.00. Although not sold in Connecticut stores, this recalled product may have been purchased while visiting the above noted states or may have been sent to Connecticut as a gift. The pacifiers were manufactured in Mexico and imported by Gromex Inc., of Passaic, New Jersey. Although no injuries and/or incidents have been reported, the potential for injury is high due to the pacifier mouth guard and the ventilation holes are too small and fail to meet federal safety standards, for this reason, the pacifier poses a choking hazard to young children.
Sexual Health

Polymorphism In Endostatin, An Angiogenesis Inhibitor, And Prostate Cancer Risk And Survival: A Prospective Study

UroToday.com - Angiogenesis is the process of new blood vessel formation in tumors, facilitating their growth. Endostatin is a cleavage product of collagen and is a potent inhibitor of endothelial cell proliferation and migration. Endostatin causes apoptosis in endothelial and tumor cells. Prostate cancer expresses angiogenic factors. A missense mutation in the coding region for endostatin has been described, but the polymorphism affects protein conformation rather than protein expression. Cellular assays suggested that the result is impaired endostatin binding to laminin, a basement membrane protein. In an online article in the International Journal of Cancer, Dr. Lorelei Mucci and colleagues present data from the Physicians" Health Study examining the D104N endostatin polymorphism in relation to prostate cancer risk and survival. The Physicians" Health Study was a randomized trial of aspirin and beta-carotene supplementation among 22,071 physicians ages 40-84 that was initiated in 1982. A total of 14,916 participants had samples available for this nested case-control study. The analysis identified 544 incident prostate cancer cases and 678 controls for polymorphism genotyping. Among the control men, 84.2% were wildtype homozygous (DD), 14.5% were heterozygous (DN), and 1.3% were homozygous carriers of the rare allele (NN). Carriage of the polymorphic N allele was not associated with risk of total prostate cancer risk. There was no evidence that the endostatin D104N polymorphism was associated with prostate cancers diagnosed at a younger or older age. There was also no association between carriage of the N allele and development of lethal prostate cancer. Participants whose prostate cancer contained the polymorphic allele were less likely to be overweight or obese (26%) compared to men with the DD genotype (47.8%). This large study observed no overall association between the D104N endostatin polymorphism and prostate cancer risk or prognosis. Mucci LA, Stark JR, Figg WD, Schumacher F, Li H, Abe M, Hennessy K, Stampfer MJ, Gaziano JM, Ma J, Kantoff PW Int J Cancer. 2009 Mar 11. (Epub ahead of print) 10.1002/ijc.24423 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009